Back

A comprehensive evaluation of available evidence of mavacamten in obstructive HCM: a meta-analysis of randomised controlled trials.

2 September 2024 (12:30 - 12:45)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Ahmed Elmorsy

Faculty Of Medicine - Tanta University, Tanta (Egypt)

3 More presentations in this session

Presentation thumbnail
Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Doctor M. Desai (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy
Doctor A. Milazzo (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?
Doctor M. Lima (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 12:30 CET
You may be interested in
thumbnail
Congress Session
Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy
thumbnail
Congress Presentation
Efficacy of cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials
thumbnail
Congress Session
Contemporary management of hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources